Accumulating evidence in animal models highlights that inflammation ensuing in the brain during status epilepticus (SE) may play a determinant role in ongoing seizures and their long-term detrimental consequences, independent of an infection or auto-immune cause. Studies in a multitude of animal models demonstrate that SE causes a rapid and intense inflammatory cascade in the forebrain involving interactions among neurons, reactive astrocytes, activated microglia, vascular endothelial cells and, eventually, infiltrating neutrophils and monocytes from the blood. The pathophysiological interactions among the various inflammatory molecules, and the sequence of events leading to their induction, have not yet been dissected. The broad cytokine burst and gliosis following SE is blunted in mice that have genetic ablations of COX-2 restricted to those principal forebrain neurons in which COX-2 is normally induced by SE, pointing to a role for COX-2 pathways in SE-induced inflammation including breakdown of the blood-brain barrier (BBB), which is sufficient to produce epilepsy. Previous work showed that the EP2 receptor mediates much of the COX-2 effect. We hypothesize that SE-related morbidity is largely due to activation of microglial EP2 receptors, which modulates production of cytokines that degrade the BBB.
Our specific aims are: 1. To test the hypothesis that activated microglia rather than inflammatory monocytes are responsible for EP2- regulated BBB breakdown after seizures; 2. To test the hypothesis that IL- -secreted mediator and Epac the major EP2 signaling pathway that degrades the integrity of the blood-brain barrier after SE; 3. To determine whether EP2 activation plays a dominant role in the development of epilepsy or its comorbidities after SE. To address these aims we employ in vitro culture models of the BBB and in vivo SE models with cell- specific conditional knockouts of EP2. Immunohistochemical, western blot, FACS, qRT-PCR, EEG and behavioral assays are performed.

Public Health Relevance

Status epilepticus, consisting of a continuous seizure that lasts longer than 5-30 min, is a life-threatening neurological emergency often refractory to available treatment options. The ensuing brain inflammation and breakdown of the blood-brain barrier are responsible for substantial morbidity, in part mediated by the EP2 receptor for prostaglandin E2. Our work should identify the molecular and cellular basis for EP2's role.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS097776-01
Application #
9159612
Study Section
Clinical Neuroplasticity and Neurotransmitters Study Section (CNNT)
Program Officer
Leenders, Miriam
Project Start
2016-05-15
Project End
2021-04-30
Budget Start
2016-05-15
Budget End
2017-04-30
Support Year
1
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Emory University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Rojas, Asheebo; Wang, Wenyi; Glover, Avery et al. (2018) Beneficial Outcome of Urethane Treatment Following Status Epilepticus in a Rat Organophosphorus Toxicity Model. eNeuro 5:
Rojas, Asheebo; Ganesh, Thota; Walker, Alec et al. (2017) Ethylatropine Bromide as a Peripherally Restricted Muscarinic Antagonist. ACS Chem Neurosci 8:712-717
Aronica, Eleonora; Bauer, Sebastian; Bozzi, Yuri et al. (2017) Neuroinflammatory targets and treatments for epilepsy validated in experimental models. Epilepsia 58 Suppl 3:27-38
Dingledine, Raymond; Coulter, Douglas A; Fritsch, Brita et al. (2017) Transcriptional profile of hippocampal dentate granule cells in four rat epilepsy models. Sci Data 4:170061
Galanopoulou, Aristea S; Wong, Michael; Binder, Devin et al. (2016) 2014 Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression. Epilepsy Curr 16:187-91
Dlugos, Dennis; Worrell, Greg; Davis, Kathryn et al. (2016) 2014 Epilepsy Benchmarks Area III: Improve Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects. Epilepsy Curr 16:192-7
Caplan, Rochelle; Mefford, Heather; Berl, Madison et al. (2016) 2014 Epilepsy Benchmarks Area I: Understanding the Causes of the Epilepsies and Epilepsy-Related Neurologic, Psychiatric, and Somatic Conditions. Epilepsy Curr 16:182-6
Long, Cara; Fureman, Brandy; Dingledine, Ray (2016) 2014 Epilepsy Benchmarks: Progress and Opportunities. Epilepsy Curr 16:179-81
Varvel, Nicholas H; Neher, Jonas J; Bosch, Andrea et al. (2016) Infiltrating monocytes promote brain inflammation and exacerbate neuronal damage after status epilepticus. Proc Natl Acad Sci U S A 113:E5665-74
Dingledine, Ray; Hassel, Bjørnar (2016) A New Approach for Epilepsy. Cerebrum 2016:

Showing the most recent 10 out of 12 publications